Report updated May 20, 2026
Johns Hopkins Antibiotic Guide
For clinicians and medical professionals requiring evidence-based, frequently updated decision support at the point of care.
Johns Hopkins Antibiotic Guide is an established medical app that is available. With a 4.8/5 rating from 5K reviews, it shows polarized user reception. Users particularly appreciate comprehensive antibiotic reference content provides essential clinical support for hospitalists and infectious disease specialists, though restrictive device management policies block access for users switching between multiple mobile phones remains a common concern.
What is Johns Hopkins Antibiotic Guide?
Johns Hopkins Antibiotic Guide is a clinical reference app for medical professionals, providing evidence-based antimicrobial, HIV, diabetes, and psychiatry guidelines on iOS and Android.
Clinicians hire this app to access verified, expert-curated medical data at the point of care, reducing the risk of diagnostic or dosing errors during hospital shifts.
Current Momentum
v1.40 · 1mo ago
MaintenanceNo new feature builds or events in recent patches; the app ships minor updates focused on payment processing at a roughly 3-month cadence.
Active Nemesis
AMBOSS Medical Knowledge
By AMBOSS
Other Rivals
7-Day Rank Pulse 🇺🇸
MedicalNo ranking data
Rating Pulse 🇺🇸
Recent User MoodAI-powered deep analysis surfacing high-signal insights. Still in beta, accuracy improves daily. For informational purposes only.
What makes this app unique?
What Does It Look Like?
How Is The App's Momentum Right Now?
Loading...
What Are The Key Features?
Curated antimicrobial, HIV, diabetes, and psychiatry clinical references updated monthly by Johns Hopkins experts
Clinical application, safety, and ethical protocols for psychedelic medicine added to the psychiatry module
Enhanced search functionality for rapid access to drug interactions, dosing, and differential diagnoses
How much does it cost?
- Free 14-day trial
- $29.99/year per guide
- $79.99/year for 4-guide bundle
Subscription model anchored at $29.99 per guide, with a bundle discount to drive higher average revenue per user.
Who Built It?
Unbound Medicine
Equipping healthcare professionals with evidence-based clinical decision support and integrated reference tools at the point of care.
Portfolio
13
Apps
Who is Unbound Medicine?
Unbound Medicine has established a defensible position by pivoting from standalone medical utilities to integrated clinical suites that consolidate multiple peer-reviewed references into a single workflow. Their primary moat is a network of high-prestige institutional partnerships, including Johns Hopkins Medicine and the American Academy of Pediatrics, which provides a level of authoritative credibility difficult for pure-tech competitors to replicate. The recent acquisition by MPS Limited marks a strategic inflection point, signaling an move toward international expansion and the integration of AI-driven tools into their existing evidence-based platform.
Who is Unbound Medicine for?
- Professional nurses
- Physicians
- Medical students
- Researchers requiring mobile access to peer-reviewed clinical data
Portfolio momentum
With 92 releases across 53 active apps in the last 6 months, the publisher maintains an exceptionally high update cadence for its clinical databases.
What other apps does Unbound Medicine make?
DSM-5-TR® Diagnosis Handbook
Davis's Drug Guide - Nurses
5-Minute Emergency Medicine
Nursing Central
Oxford Handbook Clinical Med
Oxford Emergency Medicine
What do users think recently?
Medium confidence · Latest 60 of 100 total reviews analyzed · Based on 100 reviews. Signal may be noisy.
How did the latest release land?
What is the recent mood?
Recent user voice shows a mixed sentiment. Users appreciate comprehensive antibiotic reference content provides essential clinical support for hospitalists and infectious disease specialists, but report restrictive device management policies block access for users switching between multiple mobile phones.
What Users Love
What Frustrates Users
What Users Want
What is the competitive landscape for Johns Hopkins Antibiotic Guide?
How's The Medical Market?
How does it evolve in the Medical market?
| Country | Category | Chart | Rank | Change |
|---|---|---|---|---|
| 🇯🇵 Japan | Medical | AndroidGrossing | #28 | ▼4 |
| 🇺🇸 US | Medical | iOSGrossing | #33 |
The rivals identified
The Nemesis
Head to Head
The target app must leverage its specific Johns Hopkins brand authority to defend against AMBOSS's superior platform breadth and integrated educational features.
What sets Johns Hopkins Antibiotic Guide apart
Focuses exclusively on high-trust, curated Johns Hopkins content which provides a specific brand-authority advantage.
Offers a streamlined, reference-first interface that minimizes cognitive load for clinicians needing rapid answers.
What's AMBOSS Medical Knowledge's Edge
Leverages a broader ecosystem of medical knowledge that supports the entire lifecycle of a medical professional.
Utilizes advanced search and cross-referencing capabilities that allow users to navigate complex clinical topics faster.
Contenders
Delivers highly specialized, procedure-specific anesthesia calculators and drug dosing tools for high-stakes clinical environments.
Maintains a deep, narrow focus on anesthesia-specific workflows that provides superior utility for that specific demographic.
Doximity
★4.8 (191.5K)Doximity
⚡Doximity acts as a massive professional network for clinicians, creating a high-frequency utility that captures the same target audience's attention.
Provides a secure, HIPAA-compliant communication layer that integrates directly into the clinician's daily workflow.
Offers a massive professional directory and news feed that creates a network effect the target app lacks.
OpenEvidence
★4.9 (8.9K)OpenEvidence Inc.
⚡OpenEvidence uses AI to synthesize medical literature, directly challenging the target app's value proposition of providing expert-curated clinical recommendations.
Utilizes generative AI to provide instant, evidence-based answers to complex clinical queries in real-time.
Aggregates and summarizes vast amounts of peer-reviewed literature faster than traditional manual editorial processes.
Peers
athenaPatient
★4.9 (133.9K)athenahealth
🚀While patient-facing, it occupies the same medical ecosystem and competes for the clinician's attention via EHR integration.
Connects directly to the EHR to facilitate patient-provider communication and administrative workflow management.
Focuses on the patient-side experience of clinical care rather than the provider's reference-based decision support.
Migraine Buddy: Track Headache
★4.8 (64.8K)Voluntis
⚡Represents a specialized clinical tracking tool that competes for the same medical category space.
Provides longitudinal data tracking for specific chronic conditions, offering insights that static guides cannot.
Engages users through community-driven support and symptom logging rather than clinical reference material.
New Kids on the Block
Integrates AI-powered motion tracking to provide personalized physical therapy guidance directly to the patient.
Shifts the clinical model from passive reference material to active, AI-driven therapeutic intervention.
Kaia Health
★4.7 (6.2K)Kaia Health Software GmbH
⚡Emerging as a digital health platform that leverages AI to provide clinical-grade guidance for chronic pain management.
Combines multi-modal therapy (exercise, relaxation, education) into a single, cohesive digital health program.
Uses computer vision to provide real-time feedback on exercise form, replacing the need for manual clinical oversight.
The outtake for Johns Hopkins Antibiotic Guide
Strengths to defend, gaps to attack
Core Strengths
- Brand authority of Johns Hopkins content sustains high-trust clinical adoption
- Monthly content update cadence maintains relevance in fast-moving infectious disease fields
- Point-of-care search utility minimizes cognitive load for hospitalists
Critical Frictions
- Restrictive device-locking policies drive high churn among multi-device users
- Opaque subscription billing processes trigger negative sentiment
- Technical instability in purchase restoration flows blocks access to paid content
Growth Levers
- Expansion into wearable-integrated clinical alerts
- B2B partnerships with hospital systems for enterprise-wide access
- AI-driven natural language query integration to compete with OpenEvidence
Market Threats
- AMBOSS's integrated educational ecosystem siphons professional attention
- OpenEvidence's AI synthesis reduces the value of manual editorial curation
- High-velocity digital health platforms shift user expectations toward active intervention
What are the next best moves?
Enable multi-device account syncing because device-locking is the top churn driver → improve retention
User reviews explicitly cite device-locking as a major frustration and churn trigger.
Trade-off: Push the wearable companion app sprint to Q3 — wearables waitlist is smaller than current churn volume.
Audit subscription billing flow because opaque charges trigger high-frequency negative sentiment → reduce refund surge
Customers report being charged without clear warning after trial periods.
Trade-off: Pause the price-test on the annual tier — refund surge has 4x the revenue impact.
A counter-intuitive read
The app's restrictive device-locking policy is not a security feature but a legacy monetization constraint that is actively accelerating the migration of power users to AMBOSS.
Feature Gaps vs Competitors
- Interactive Q&A and study modes (available in AMBOSS)
- Unified cross-platform educational ecosystem (available in AMBOSS)
- Generative AI-based clinical query synthesis (available in OpenEvidence)
Key Takeaways
The app maintains high utility as a clinical reference, but its reputation is damaged by restrictive device-locking and opaque billing, so the PM must prioritize account-syncing and billing transparency to defend the core user base.
Where Is It Heading?
Mixed Signals
The clinical reference market is consolidating around platforms that offer integrated educational and AI-driven synthesis, leaving static guides like this one exposed to churn. The app's future depends on transitioning from a single-device reference tool to a multi-device, AI-augmented clinical assistant to match the utility of modern rivals.
Restrictive device-locking policies continue to drive negative sentiment, which compounds the churn risk among professional users who rely on multiple devices.
The latest update to the psychiatry guide shows active content investment, ensuring the app remains a primary reference for specialized clinical practitioners.